With eagerly anticipated Phase III data imminent on the atopic dermatitis drug lebrikizumab, Almirall SA has got off to a good start for what will be a pivotal third quarter by obtaining EU approval for its actinic keratosis (AK) therapy Klisyri.
Two months after receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), the European Commission...






